CYTOSORBENTS CORPORATION Contract Liability (Deferred Revenue)
CYTOSORBENTS CORPORATION (CTSO) had Contract Liability (Deferred Revenue) of $1.13 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-06
- 2026-06-30: Contract with Customer, Liability, Current $1.13M.
- 2026-03-31: Contract with Customer, Liability, Current $34.00K.
- 2025-12-31: Contract with Customer, Liability, Current $182.00K.
- 2025-09-30: Contract with Customer, Liability, Current $403.00K.
| Period end | Contract with Customer, Liability, Current | Contract with Customer, Liability, Current as first filed |
|---|---|---|
| 2026-06-30 | $1.13M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $34.00K 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $182.00K 10-Q · filed 2026-05-13 | |
| 2025-09-30 | $403.00K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $361.00K 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $546.03K 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $596.00K 10-K · filed 2026-03-30 | $419.33K 10-K · filed 2025-03-31 |
| 2023-12-31 | $1.38M 10-K · filed 2025-03-31 | |
| 2022-12-31 | $1.52M 10-K · filed 2024-03-15 | |
| 2021-12-31 | $1.95M 10-K · filed 2023-03-09 | |
| 2020-12-31 | $728.35K 10-K · filed 2022-03-10 | |
| 2020-03-31 | $32.30K 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $0.00 10-K · filed 2021-03-09 | $171.84K 10-K · filed 2020-03-05 |
| 2019-09-30 | $92.31K 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $43.36K 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $10.46K 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $42.22K 10-K · filed 2020-03-05 | |
| 2018-09-30 | $35.11K 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $39.33K 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $43.59K 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $30.38K 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |